Trust Score calculated by AI analyzing study rigor, sample size (n), and the scientific source impact factor.
5.4% of centenarians harbor neutralizing type I interferon autoantibodies, indicating prevalence plateaus at extreme age
Summary
“5.4% of centenarians have neutralizing IFN‑I autoantibodies, showing prevalence levels off compared with individuals aged ≥80 years.”
Adrian Castro created Biohacker Age to have a place to closely follow longevity and biological optimization research without relying on sensationalist headlines. Content is produced with AI assistance from scientific literature and is editorially reviewed before publishing.
About our methodology →The Question
Understanding why some individuals reach 100 years while others succumb earlier remains a central puzzle in gerontology. Researchers have long observed that autoantibodies that neutralize type I interferons (IFN‑I) increase with age and raise susceptibility to severe viral infections. Yet, it is unclear whether these antibodies simply accumulate with age or if they become a limiting factor for achieving extreme longevity.
The Experiment
Lead author Mø rk and colleagues from the Department of Biomedicine coordinated a multinational cross‑sectional serological screening. The study enrolled centenarians from four distinct cohorts: Denmark (n = 258), Colombia (n = 99), Australia (n = 281), and Japan (n = 300), totaling 938 participants. Blood samples were tested for neutralizing IFN‑I auto‑antibodies using a validated virus‑based neutralization assay, providing a binary outcome (presence vs. absence).
What They Found
Overall, 51 of the 938 centenarians (5.4%) tested positive for neutralizing IFN‑I auto‑antibodies. Prevalence varied by region, from 3.3% in Japan to 9.1% in Colombia. This rate mirrors the plateau observed in individuals aged ≥80 years, indicating that the frequency of these auto‑antibodies does not continue to climb beyond the ninth decade.
Why It Matters
Type I interferons are frontline cytokines that orchestrate antiviral defenses. Neutralization by auto‑antibodies can blunt this response, predisposing carriers to life‑threatening viral illnesses. The finding that a modest fraction of centenarians still harbor such antibodies suggests that while they are compatible with reaching 100 years, they may impose a hidden mortality risk that prevents even longer lifespans.
Study Limitations
- The design is observational; causality between auto‑antibody presence and mortality cannot be established.
- Cross‑sectional sampling captures a single time point, offering no insight into how antibody levels evolve within individuals.
- Cohorts differ in ethnicity, healthcare access, and screening protocols, which may introduce heterogeneity.
Practical Application
Current evidence does not support a specific intervention for healthy adults based on these findings. Prospective longitudinal studies that track IFN‑I auto‑antibody dynamics and related infection outcomes are needed before any actionable protocol can be recommended.
Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.
Legal Notice
Medical Disclaimer: This content is for informational and educational purposes only. It is not intended to substitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or supplementation.
Science in your inbox
The most relevant studies of the week, curated and analyzed.
No spam. Unsubscribe anytime.